Hims & Hers Increases 2026 Revenue Outlook to $3 Billion

Hims & Hers Health Inc raised its 2026 revenue forecast to a range of $2.8 billion to $3 billion on Monday evening. The updated outlook climbs from a previous estimate of $2.7 billion to $2.9 billion as demand for personalized healthcare offerings accelerates. This guidance revision signals confidence in the company's shift toward branded partnerships following its pivot away from compounded weight-loss alternatives.

### Wegovy Integration Drives Growth Outlook The revised forecast follows a March agreement with Novo Nordisk A/S-B to offer the weight-loss drug Wegovy directly on the Hims platform. This partnership ended a legal dispute between the two firms that began after Hims launched a low-cost compounded version of the treatment. Hims has since discontinued that compounded alternative to focus on the official Novo Nordisk product.